Functional prostacyclin synthase promoter polymorphisms impact in pulmonary arterial hypertension

Robert Stearman, Amber R. Cornelius, Xiao Lu, David S. Conklin, Mark J. Del Rosario, Anita M. Lowe, Mihret T. Elos, Lynsey M. Fettig, Randall E. Wong, Naoko Hara, Joy D. Cogan, John A. Phillips, Matthew R. Taylor, Brian B. Graham, Rubin M. Tuder, James E. Loyd, Mark W. Geraci

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Rationale: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary artery pressure, vascular remodeling, and ultimately right ventricular heart failure. PAH can have a genetic component (heritable PAH), most often through mutations of bone morphogenetic protein receptor 2, and idiopathic and associated forms. Heritable PAH is not completely penetrant within families, with approximately 20% concurrence of inactivating bone morphogenetic protein receptor 2 mutations and delayed onset of PAH disease. Because one of the treatment options is using prostacyclin analogs, we hypothesized that prostacyclin synthase promoter sequence variants associated with increased mRNA expression may play a protective role in the bone morphogenetic protein receptor 2 unaffected carriers. Objectives: To characterize the range of prostacyclin synthase promoter variants and assess their transcriptional activities in PAHrelevant cell types. To determine the distribution of prostacyclin synthase promoter variants in PAH, unaffected carriers in heritable PAH families, and control populations. Methods: Polymerase chain reaction approaches were used to genotype prostacyclin synthase promoter variants in more than 300 individuals. Prostacyclin synthase promoter haplotypes' transcriptional activities were determined with luciferase reporter assays. Measurements and Main Results:Weidentified a comprehensive set of prostacyclin synthase promoter variants and tested their transcriptional activities in PAH-relevant cell types. We demonstrated differences of prostacyclin synthase promoter activities dependent on their haplotype. Conclusions: Prostacyclin synthase promoter sequence variants exhibit a range of transcriptional activities.We discovered a significant bias for more active prostacyclin synthase promoter variants in unaffected carriers as compared with affected patients with PAH.

Original languageEnglish (US)
Pages (from-to)1110-1120
Number of pages11
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume189
Issue number9
DOIs
StatePublished - May 1 2014
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Bone Morphogenetic Protein Receptors
Bone Morphogenetic Protein 2
Haplotypes
prostacyclin synthetase
Mutation
Epoprostenol
Luciferases
Pulmonary Artery
Heart Failure
Genotype
Pressure
Polymerase Chain Reaction
Messenger RNA
Population

Keywords

  • Genetic polymorphism
  • Genetic predisposition to disease
  • Lung diseases
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Medicine(all)

Cite this

Functional prostacyclin synthase promoter polymorphisms impact in pulmonary arterial hypertension. / Stearman, Robert; Cornelius, Amber R.; Lu, Xiao; Conklin, David S.; Del Rosario, Mark J.; Lowe, Anita M.; Elos, Mihret T.; Fettig, Lynsey M.; Wong, Randall E.; Hara, Naoko; Cogan, Joy D.; Phillips, John A.; Taylor, Matthew R.; Graham, Brian B.; Tuder, Rubin M.; Loyd, James E.; Geraci, Mark W.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 189, No. 9, 01.05.2014, p. 1110-1120.

Research output: Contribution to journalArticle

Stearman, R, Cornelius, AR, Lu, X, Conklin, DS, Del Rosario, MJ, Lowe, AM, Elos, MT, Fettig, LM, Wong, RE, Hara, N, Cogan, JD, Phillips, JA, Taylor, MR, Graham, BB, Tuder, RM, Loyd, JE & Geraci, MW 2014, 'Functional prostacyclin synthase promoter polymorphisms impact in pulmonary arterial hypertension', American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 9, pp. 1110-1120. https://doi.org/10.1164/rccm.201309-1697OC
Stearman, Robert ; Cornelius, Amber R. ; Lu, Xiao ; Conklin, David S. ; Del Rosario, Mark J. ; Lowe, Anita M. ; Elos, Mihret T. ; Fettig, Lynsey M. ; Wong, Randall E. ; Hara, Naoko ; Cogan, Joy D. ; Phillips, John A. ; Taylor, Matthew R. ; Graham, Brian B. ; Tuder, Rubin M. ; Loyd, James E. ; Geraci, Mark W. / Functional prostacyclin synthase promoter polymorphisms impact in pulmonary arterial hypertension. In: American Journal of Respiratory and Critical Care Medicine. 2014 ; Vol. 189, No. 9. pp. 1110-1120.
@article{01a7199ba187425c8ca3c42d3d1186e7,
title = "Functional prostacyclin synthase promoter polymorphisms impact in pulmonary arterial hypertension",
abstract = "Rationale: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary artery pressure, vascular remodeling, and ultimately right ventricular heart failure. PAH can have a genetic component (heritable PAH), most often through mutations of bone morphogenetic protein receptor 2, and idiopathic and associated forms. Heritable PAH is not completely penetrant within families, with approximately 20{\%} concurrence of inactivating bone morphogenetic protein receptor 2 mutations and delayed onset of PAH disease. Because one of the treatment options is using prostacyclin analogs, we hypothesized that prostacyclin synthase promoter sequence variants associated with increased mRNA expression may play a protective role in the bone morphogenetic protein receptor 2 unaffected carriers. Objectives: To characterize the range of prostacyclin synthase promoter variants and assess their transcriptional activities in PAHrelevant cell types. To determine the distribution of prostacyclin synthase promoter variants in PAH, unaffected carriers in heritable PAH families, and control populations. Methods: Polymerase chain reaction approaches were used to genotype prostacyclin synthase promoter variants in more than 300 individuals. Prostacyclin synthase promoter haplotypes' transcriptional activities were determined with luciferase reporter assays. Measurements and Main Results:Weidentified a comprehensive set of prostacyclin synthase promoter variants and tested their transcriptional activities in PAH-relevant cell types. We demonstrated differences of prostacyclin synthase promoter activities dependent on their haplotype. Conclusions: Prostacyclin synthase promoter sequence variants exhibit a range of transcriptional activities.We discovered a significant bias for more active prostacyclin synthase promoter variants in unaffected carriers as compared with affected patients with PAH.",
keywords = "Genetic polymorphism, Genetic predisposition to disease, Lung diseases, Pulmonary hypertension",
author = "Robert Stearman and Cornelius, {Amber R.} and Xiao Lu and Conklin, {David S.} and {Del Rosario}, {Mark J.} and Lowe, {Anita M.} and Elos, {Mihret T.} and Fettig, {Lynsey M.} and Wong, {Randall E.} and Naoko Hara and Cogan, {Joy D.} and Phillips, {John A.} and Taylor, {Matthew R.} and Graham, {Brian B.} and Tuder, {Rubin M.} and Loyd, {James E.} and Geraci, {Mark W.}",
year = "2014",
month = "5",
day = "1",
doi = "10.1164/rccm.201309-1697OC",
language = "English (US)",
volume = "189",
pages = "1110--1120",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "9",

}

TY - JOUR

T1 - Functional prostacyclin synthase promoter polymorphisms impact in pulmonary arterial hypertension

AU - Stearman, Robert

AU - Cornelius, Amber R.

AU - Lu, Xiao

AU - Conklin, David S.

AU - Del Rosario, Mark J.

AU - Lowe, Anita M.

AU - Elos, Mihret T.

AU - Fettig, Lynsey M.

AU - Wong, Randall E.

AU - Hara, Naoko

AU - Cogan, Joy D.

AU - Phillips, John A.

AU - Taylor, Matthew R.

AU - Graham, Brian B.

AU - Tuder, Rubin M.

AU - Loyd, James E.

AU - Geraci, Mark W.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Rationale: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary artery pressure, vascular remodeling, and ultimately right ventricular heart failure. PAH can have a genetic component (heritable PAH), most often through mutations of bone morphogenetic protein receptor 2, and idiopathic and associated forms. Heritable PAH is not completely penetrant within families, with approximately 20% concurrence of inactivating bone morphogenetic protein receptor 2 mutations and delayed onset of PAH disease. Because one of the treatment options is using prostacyclin analogs, we hypothesized that prostacyclin synthase promoter sequence variants associated with increased mRNA expression may play a protective role in the bone morphogenetic protein receptor 2 unaffected carriers. Objectives: To characterize the range of prostacyclin synthase promoter variants and assess their transcriptional activities in PAHrelevant cell types. To determine the distribution of prostacyclin synthase promoter variants in PAH, unaffected carriers in heritable PAH families, and control populations. Methods: Polymerase chain reaction approaches were used to genotype prostacyclin synthase promoter variants in more than 300 individuals. Prostacyclin synthase promoter haplotypes' transcriptional activities were determined with luciferase reporter assays. Measurements and Main Results:Weidentified a comprehensive set of prostacyclin synthase promoter variants and tested their transcriptional activities in PAH-relevant cell types. We demonstrated differences of prostacyclin synthase promoter activities dependent on their haplotype. Conclusions: Prostacyclin synthase promoter sequence variants exhibit a range of transcriptional activities.We discovered a significant bias for more active prostacyclin synthase promoter variants in unaffected carriers as compared with affected patients with PAH.

AB - Rationale: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary artery pressure, vascular remodeling, and ultimately right ventricular heart failure. PAH can have a genetic component (heritable PAH), most often through mutations of bone morphogenetic protein receptor 2, and idiopathic and associated forms. Heritable PAH is not completely penetrant within families, with approximately 20% concurrence of inactivating bone morphogenetic protein receptor 2 mutations and delayed onset of PAH disease. Because one of the treatment options is using prostacyclin analogs, we hypothesized that prostacyclin synthase promoter sequence variants associated with increased mRNA expression may play a protective role in the bone morphogenetic protein receptor 2 unaffected carriers. Objectives: To characterize the range of prostacyclin synthase promoter variants and assess their transcriptional activities in PAHrelevant cell types. To determine the distribution of prostacyclin synthase promoter variants in PAH, unaffected carriers in heritable PAH families, and control populations. Methods: Polymerase chain reaction approaches were used to genotype prostacyclin synthase promoter variants in more than 300 individuals. Prostacyclin synthase promoter haplotypes' transcriptional activities were determined with luciferase reporter assays. Measurements and Main Results:Weidentified a comprehensive set of prostacyclin synthase promoter variants and tested their transcriptional activities in PAH-relevant cell types. We demonstrated differences of prostacyclin synthase promoter activities dependent on their haplotype. Conclusions: Prostacyclin synthase promoter sequence variants exhibit a range of transcriptional activities.We discovered a significant bias for more active prostacyclin synthase promoter variants in unaffected carriers as compared with affected patients with PAH.

KW - Genetic polymorphism

KW - Genetic predisposition to disease

KW - Lung diseases

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=84899804206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899804206&partnerID=8YFLogxK

U2 - 10.1164/rccm.201309-1697OC

DO - 10.1164/rccm.201309-1697OC

M3 - Article

VL - 189

SP - 1110

EP - 1120

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 9

ER -